Edit

Castle Biosciences

https://castlebiosciences.com/

Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Our tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information.

Our DecisionDx tests provide personalized, clinically actionable information to help healthcare providers and patients make more informed decisions about their treatment plans. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Our newest proprietary gene expression profile test, DecisionDx® DiffDx™-Melanoma is designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions.

We also have active research and development programs for tests in other dermatologic diseases with high clinical need.

Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com.